Skip to main content

Peer Review reports

From: First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations

Original Submission
10 Apr 2022 Submitted Original manuscript
21 May 2022 Reviewed Reviewer Report
18 Aug 2022 Reviewed Reviewer Report
8 Sep 2022 Reviewed Reviewer Report - Igor Samoylenko
25 Oct 2022 Author responded Author comments - Xuan Wang
Resubmission - Version 2
25 Oct 2022 Submitted Manuscript version 2
30 Oct 2022 Reviewed Reviewer Report
2 Nov 2022 Reviewed Reviewer Report
17 Nov 2022 Author responded Author comments - Xuan Wang
Resubmission - Version 3
17 Nov 2022 Submitted Manuscript version 3
Publishing
18 Nov 2022 Editorially accepted
4 Jan 2023 Article published 10.1186/s12916-022-02669-7

You can find further information about peer review here.

Back to article page